[
    {
        "題別": "單",
        "題號": "1",
        "題目": "透亮細胞腎臟癌(Clear cell RCC)為下列何種基因去活性所 造成？",
        "選項": [
            "A. proto-oncogene MET。",
            "B. von Hippel-Lindau (VHL) gene。",
            "C. fumarate hydratase gene。",
            "D. Birt Hogg Dube (BHD) gene。",
            "E. Retinoblastoma (Rb) gene。"
        ],
        "答案": "B",
        "出處": "NCCN Guidelines Version 4.2023\nHereditary Renal Cell Carcinoma,\nHERED-RCC-2"
    },
    {
        "題別": "單",
        "題號": "2",
        "題目": "下列何種腎臟癌之標靶治療藥物會引起hand and foot syndrome反應？",
        "選項": [
            "A. Pazopanib。",
            "B. Bevacizumab。",
            "C. Temsirolimus。",
            "D. Sunitinib。",
            "E. Everolimus。"
        ],
        "答案": "D",
        "出處": "JNCCN–Journal of the National\nComprehensive Cancer Network |\nVolume 9 Supplement 1 | February\n2011; S14-16"
    },
    {
        "題別": "單",
        "題號": "3",
        "題目": "高度進展的腸胃道基質瘤(gastrintestinal stromal tumor, GIST)之手術原則與imatinib使用，以下敘述何者正確？ (甲)轉移性GIST以Imatinib治療，若轉移病灶縮小到可手術 時，宜將轉移灶切除。此時imatinib可暫時停用(乙)多發肝 轉移之GIST，對imatinib反應良好時，應將GIST的原發病 灶切除。(丙)Imatinib用400mg qd效果不彰時，可增量到 800mg qd。(丁)Imatinib是一種multi-kinase inhibitor。 (戊)Imatinib是一種tyrosine-kinase inhibitor。",
        "選項": [
            "A. 甲、乙、丙。",
            "B. 甲、丙、戊。",
            "C. 丙、戊。",
            "D. 乙、丙、戊。",
            "E. 乙、丙、丁。"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 702, 1279"
    },
    {
        "題別": "單",
        "題號": "4",
        "題目": "所謂“期別移轉(Stage Migration) ”現象常發生於癌症治療的 處置改變，下列何者為錯誤？",
        "選項": [
            "A. 採用新的檢查工具(例如正子造影PET Scan)。",
            "B. 採用更侵襲的檢查方法(例如骨髓切片)。",
            "C. 採用更先進的治療方法(例如冷凍治療)。",
            "D. 採用術前輔助性治療(例如化學及放射治療)。",
            "E. 採用淋巴結廓清手術。"
        ],
        "答案": "C",
        "出處": "Ann Surg 2012; 255: 50-58."
    },
    {
        "題別": "單",
        "題號": "5",
        "題目": "Subsequent to a screening colonoscopy, a 48 Y/O man was diagnosed with a right-sided colorectal cancer. Clinical staging studies revealed no distal metastasis, and bowel resection was performed. The surgeon met with oncologist who indicated that in addition to standard pathologic examination, the primary tumor specimen should also have:",
        "選項": [
            "A. Microsatellite status (stable or unstable) testing。",
            "B. EGFR status testing。",
            "C. K-ras status testing。",
            "D. Braf status testing。",
            "E. K-ras and Braf status testing。"
        ],
        "答案": "A",
        "出處": "NCCN Guidelines Version 2.2023\nColon Cancer, COL-B 4 OF 8"
    },
    {
        "題別": "單",
        "題號": "6",
        "題目": "Bevacizumab (Avastin) 與含有irinotecan / 5-FU/ leucovorin 或 5-FU/ leucovorin 的化學療法合併使用，可以 作為轉移性大腸或直腸癌患者的第一線治療，其臨床不良 反應為：",
        "選項": [
            "A. 胃腸穿孔。",
            "B. 胃腸出血。",
            "C. 動脈血栓栓塞。",
            "D. 高血壓。",
            "E. 以上皆是。"
        ],
        "答案": "E",
        "出處": "1. Micromedex 2023,\n2. Drug@FDA\n3. Avastin衛生署核准藥品仿單"
    },
    {
        "題別": "單",
        "題號": "7",
        "題目": "以下何者不專屬於inhibitors of intracellular signaling pathways ？",
        "選項": [
            "A. PI3K。",
            "B. HER2。",
            "C. AKT。",
            "D. mTOR (mammalian target of rapamycin)。",
            "E. ERK。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 726"
    },
    {
        "題別": "單",
        "題號": "8",
        "題目": "乳癌病患接受輔助性標靶治療藥物時(Trastuzumab)，最常 需要的檢查為何？",
        "選項": [
            "A. 胸部X光。",
            "B. 骨骼掃描。",
            "C. 乳房X光攝影。",
            "D. 心臟功能檢查。",
            "E. 肝臟超音波。"
        ],
        "答案": "D",
        "出處": "NCCN Guidelines Version 4.2023\nBreast Cancer, BINV-17"
    },
    {
        "題別": "單",
        "題號": "9",
        "題目": "關於正子掃描(PET Scan)敘述，何者有誤？",
        "選項": [
            "A. 可以運用於癌症病患治療前Staging。",
            "B. 可以運用於癌症病患治療後Re-Staging。",
            "C. 可以運用於癌症合併糖尿病患者。",
            "D. 可以運用於診斷泌尿系統癌症。",
            "E. 可以運用於排除癌症可能性。"
        ],
        "答案": "E",
        "出處": "Principles and Practice of Surgical\nOncology, 2010"
    },
    {
        "題別": "單",
        "題號": "10",
        "題目": "標靶藥物治療原則，何者有誤？",
        "選項": [
            "A. 標靶藥物治療前要確認標靶存在。",
            "B. 標靶藥物治療效果優於化學藥物治療。",
            "C. 標靶藥物治療副作用低於化學藥物治療。",
            "D. 標靶藥物治療可以使用於neoadjuvant及 adjuvant therapy。",
            "E. 標靶藥物治療可以合併化學藥物治療。"
        ],
        "答案": "B",
        "出處": "Principles and Practice of Surgical\nOncology, 2010"
    },
    {
        "題別": "單",
        "題號": "11",
        "題目": "標靶藥物治療後腫瘤復發，何者有誤？",
        "選項": [
            "A. 再度確認復發腫瘤histopathology決定新治療策略。",
            "B. 考慮重啟化學藥物治療。",
            "C. 放棄標靶藥物治療。",
            "D. 雙重標靶藥物治療。",
            "E. 使用標靶載體化學藥物治療。"
        ],
        "答案": "C",
        "出處": "Principles and Practice of Surgical\nOncology, 2010"
    },
    {
        "題別": "單",
        "題號": "12",
        "題目": "下列Biomarkers可以預測，轉移性大腸癌對於anti-EGFR單 株抗體治療沒有效果，何者不是？",
        "選項": [
            "A. KRAS mutation。",
            "B. BRAF mutation。",
            "C. EGFR expression by IHC stain。",
            "D. PIK3CA exon 20 mutation。",
            "E. NRAS mutation。"
        ],
        "答案": "C",
        "出處": "Wendy De Roock et al. Lancet\nOncol 2010; 11: 753–62."
    },
    {
        "題別": "單",
        "題號": "13",
        "題目": "下列有關胃腸間質瘤(Gastrointestinal stromal tumor)之敘 述何者有誤？",
        "選項": [
            "A. 最常發生在胃。",
            "B. 最常轉移至肝臟。",
            "C. 胃的GIST中KIT基因突變的位置最常見是exon 9。",
            "D. 根據「腫瘤的大小」、「細胞分裂的情況」 和「部位」 來分類其惡性傾向的相對風險。",
            "E. 有10～15%的GIST臨床上無法測得KIT或 PDGFRA的基 因突變。"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 767-769"
    },
    {
        "題別": "單",
        "題號": "14",
        "題目": "下列有關Neuroendocrine tumor (NET)藥物治療之敘述何 者有誤？",
        "選項": [
            "A. mTOR是一種serine-threonine kinase。",
            "B. mTOR是一種tyrosine kinase。",
            "C. mTOR inhibitor 可有效延長NET之progression free survival。",
            "D. Somatostatin analog可減緩carcinoid syndrome。",
            "E. Sunitinib可藉由阻斷VEGFR pathway延長NET之 progression free survival。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 946, 1275-1276"
    },
    {
        "題別": "單",
        "題號": "15",
        "題目": "關於胃腺癌的致癌危險因子，下列何者為錯誤？",
        "選項": [
            "A. 醃肉或魚是高危險因子。",
            "B. 抽菸是高危險因子。",
            "C. 幽門螺旋桿菌感染是高危險因子。",
            "D. 低硝酸鹽飲食是高危險因子。",
            "E. 男性是高危險因子。"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 1213-1214"
    },
    {
        "題別": "單",
        "題號": "16",
        "題目": "根據2013年美國病理學會(CAP)的指引，有關HER- 2(Human Epidermal growth factor Receptor-2)的檢驗，何 者為正確？",
        "選項": [
            "A. 若病理組織切片只看到DCIS，HER-2(3+)，則IDC也可 視為HER-2(3+)。",
            "B. 所謂免疫組織染色(IHC)為HER-2(3+)， 指complete， intense and within>30% tumor cell。",
            "C. 若HER-2(2+)，equivocal，若Ki-67>20%， 則視為HER- 2 overexpression。",
            "D. 在FISH檢驗中，HER-2/CEP17 ratio≥2.2，視為FISH Positive。",
            "E. 在FISH檢驗中，HER-2/CEP17 ratio<2.0時，若平均 HER-2 copy number≥6.0 signals/cell ，則視為FISH Positive。"
        ],
        "答案": "E",
        "出處": "DOI: 10.1200/JCO.2018.77.8738\nJournal of Clinical Oncology 36, no.\n20 (July 10, 2018) 2105-2122."
    },
    {
        "題別": "單",
        "題號": "17",
        "題目": "HER-度表現之乳癌，其標靶治療藥物，下列何者為非？",
        "選項": [
            "A. Transtuzumab。",
            "B. Lapatinib。",
            "C. Pertuzumab。",
            "D. Bevacizumab。",
            "E. T-DM1。"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 719"
    },
    {
        "題別": "單",
        "題號": "18",
        "題目": "有關膽囊癌（gallbladder cancer）下列何者為非？",
        "選項": [
            "A. 好發於男性。",
            "B. 危險因子包括膽結石，尤其是大於3公分者。",
            "C. 症狀不明顯，發現時常已晚期。",
            "D. 磁化膽囊(porcelain gallbladder) 也是重要危險因子。",
            "E. 膽囊息肉(gallbladder polyp) 大於1公分，因膽囊癌風險 升高，建議進行膽囊切除。"
        ],
        "答案": "A",
        "出處": "Sabiston 20th e, p. 1512"
    },
    {
        "題別": "單",
        "題號": "19",
        "題目": "有關肝門膽管癌（Hilar Cholangiocarcinoma）下列敘述何 者為非？",
        "選項": [
            "A. 又統稱Klatskin tumor。",
            "B. 在Bismuth-Cortette 分類中，侵犯到總肝管和右側膽管 的腫瘤為type Ⅲb。",
            "C. 和預後最重要的是手術完全切除，(margin free R0 resection)。",
            "D. 近年來手術治療改善主要是合併肝切除，使Ro resection 比例增加。",
            "E. 無法切除的病患，可考慮進行膽道內支架置放。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 1514-1518"
    },
    {
        "題別": "單",
        "題號": "20",
        "題目": "有關肝癌病患進行肝移植的考量下列何者為非？",
        "選項": [
            "A. 根據Milan criteria，腫瘤數目不宜超過三顆， 最大腫瘤 直徑不宜超過5公分。",
            "B. 肝內主要血管侵犯並非移植禁忌。",
            "C. 肝外轉移病患不適合進行移植。",
            "D. 若考慮親屬活體捐贈肝移植，目前國內受贈者 條件是遵 循UCSF criteria。",
            "E. 移植後一般必須終身服用抗排斥藥物，後續可能 的腫瘤 復發是重要課題。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 638"
    },
    {
        "題別": "單",
        "題號": "21",
        "題目": "GIST術後復發的危險因子，下列何者為非？",
        "選項": [
            "A. 長在十二指腸或直腸的腫瘤。",
            "B. KIT exon 11 deletion。",
            "C. High mitotic count。",
            "D. Incomplete resection。",
            "E. 缺少lymph node dissection者。"
        ],
        "答案": "E",
        "出處": "Sabiston 20th e, p. 767-769, 1279"
    },
    {
        "題別": "單",
        "題號": "22",
        "題目": "關於標靶藥物與作用標的，下列何者為非？",
        "選項": [
            "A. Imatinib, Bcr-abl。",
            "B. Trastuzumab, Her-2(neu)。",
            "C. Bevacizumab, VEGF。",
            "D. Gefitinib , VEGF。",
            "E. Lapatinib, ErbB1。"
        ],
        "答案": "Ｄ",
        "出處": "Sabiston 20th e, p. 702, 719, 857"
    },
    {
        "題別": "單",
        "題號": "23",
        "題目": "ERBB2基因放大的轉移性乳癌，最終對trastuzumab產生抗 藥性的原因，不包含？",
        "選項": [
            "A. IGF-I receptor過度表現活化PI3K/Akt路徑。",
            "B. EGFR/ERBB3引起之ERBB2再活化。",
            "C. PTEN受抑制引起PI3K路徑活化。",
            "D. Lapatinib可治療部分trastuzumab抗藥性。",
            "E. 多數產生抗藥性的病人其轉移病灶與原發乳癌的賀爾蒙 接受體狀態並不一致。"
        ],
        "答案": "E",
        "出處": "Disease of the breast, 5th edition,\nLippincott Williams & Wilkins,\npp.986"
    },
    {
        "題別": "單",
        "題號": "24",
        "題目": "甲狀腺癌在術前最好的診斷工具為何？",
        "選項": [
            "A. 電腦斷層(CT)。",
            "B. 頸部超音波(Sonography)。",
            "C. 細針穿刺檢查(FNA) 。",
            "D. 核磁共振(MRI)。",
            "E. 碘-131掃描(I-131 scan)。"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 897"
    },
    {
        "題別": "單",
        "題號": "25",
        "題目": "髓質性甲狀腺癌(Medullary Thyroid cancer)，術後追蹤最 好的血清指標為何？",
        "選項": [
            "A. CA-192。",
            "B. Thyroglobulin。",
            "C. Calcitonin。",
            "D. CA-199。",
            "E. PSA。"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 910"
    },
    {
        "題別": "單",
        "題號": "26",
        "題目": "下列敘述關於膽囊癌何者為非？",
        "選項": [
            "A. 膽結石是膽囊癌最常見的危險因子。",
            "B. 膽囊瘜肉也是膽囊癌危險因子，腹部超音波影 像顯示膽 囊息肉病變經手術證實85%左右是膽固醇沉著症，僅15% 左右是真正的膽囊腺瘤，膽囊息肉病變2.5公分以下建議定 期追蹤即可。",
            "C. 慢性膽囊炎病人接受腹腔鏡膽囊切除術後，病理 切片顯 示為T2膽囊癌，必須規勸病人再度手術進行肝床部分切除 及淋巴腺清除術。",
            "D. 化學療法(mitomycinFu) 對於膽囊癌的治療相當有限， 目前治療有效 比率僅10%~20%之間。",
            "E. TNM第一期膽囊癌接受單純性膽囊切除後5年存活率約 85%。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 1512"
    },
    {
        "題別": "單",
        "題號": "27",
        "題目": "關於使用標靶治療轉移性胃腸道基質瘤，下列何者為非？",
        "選項": [
            "A. 第一線用藥為imatinib mesylate。",
            "B. 腫瘤經治療後穩定與有反應其疾病無惡化存活一樣好。",
            "C. 腫瘤基因型與標靶治療效果有關。",
            "D. 第二線用藥為 pazopanib。",
            "E. 第三線用藥為 regorafenib。"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 767-769, 1229,\n1279"
    },
    {
        "題別": "單",
        "題號": "28",
        "題目": "下列有關甲狀腺癌的敘述何者有誤？",
        "選項": [
            "A. 大於一公分分化良好之甲狀腺癌應行近全或全甲狀腺切 除。",
            "B. 有Thyroid capsule 侵犯之分化良好甲狀腺癌術後應行放 射性碘治療。",
            "C. 小於一公分且無其他危險因子之分化良好之 甲狀腺癌不 需行放射性碘治療。",
            "D. 手術時腫瘤無法完全切除之分化良好甲狀腺癌 可以 External beam radiation治療。",
            "E. 術前HTG(Human Thyroglobulin) 值之高低可預測甲狀腺 癌之預後。"
        ],
        "答案": "E",
        "出處": "Sabiston 20th e, p. 886-887, 907-908"
    },
    {
        "題別": "單",
        "題號": "29",
        "題目": "下列有關胃腸道基質瘤(GIST)標靶治療藥物之敘述何者為 誤？",
        "選項": [
            "A. KIT exon 11位置發生基因突變者，其預後較佳。",
            "B. Imatinib目前為GIST合併肝臟轉移的第一線治療。",
            "C. 一開始對Imitinib有療效的病人，可能因腫瘤 基因的突變 開始惡化。",
            "D. 體液滯留是Imatinib治療常見的副作用。",
            "E. KIT 基因無突變的GIST對Imatinib治療的反應 率最好。"
        ],
        "答案": "E",
        "出處": "Sabiston 20th e, p. 767-769, 1279-\n1280; Waller CF. Imatinib Mesylate.\nRecent Results Cancer Res.\n2018;212:1-27. doi: 10.1007/978-3-\n319-91439-8_1."
    },
    {
        "題別": "單",
        "題號": "30",
        "題目": "下列有關胃癌HER2基因表現及治療的敘述何者有誤？",
        "選項": [
            "A. 胃癌病人中HER2 overexpression (過度表現) 的機率約 為6-35%。",
            "B. HER2過度表現較常見於diffuse type之胃癌。",
            "C. 使用Trastuzumab (Herceptin) 時須提防心臟功能受損。",
            "D. Trastuzumab (Herceptin) 與Cisplatin及Xeloda合用可增 加胃癌病人存活率。",
            "E. Trastuzumab (Herceptin) 作用在HER2之Eextracellular domain。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 1226"
    },
    {
        "題別": "單",
        "題號": "31",
        "題目": "一位55歲的健康婦女接受經肛門切除距離肛門邊緣6厘米處 的2厘米的直腸腫瘤。病理評估顯示低分化的T2腺癌，邊緣 陰性。 最合適的處理方式是：",
        "選項": [
            "A. 經全直腸繫膜切除",
            "B. 術後體外放射治療",
            "C. 術後體外放射治療暨化療",
            "D. 三個月內乙狀結腸鏡檢查",
            "E. 六個月內內視鏡超音波檢查"
        ],
        "答案": "A",
        "出處": "Sabiston 20th e, p. 1377-1381"
    },
    {
        "題別": "單",
        "題號": "32",
        "題目": "那個因素不應影響結直腸癌隨訪計劃 (follow-up program) 的設計？",
        "選項": [
            "A. 原發腫瘤的位置",
            "B. 患者的年齡和合併症",
            "C. 原發腫瘤的階段",
            "D. 原發腫瘤的組織學分級",
            "E. 有結直腸癌的家族史"
        ],
        "答案": "D",
        "出處": "Gemlo BT, Rothenberger DA.\nColorectal cancer surveillance. In: Wolff\nBG Fleshman JW, Beck DE et al eds.\nThe ASCRS Textbook of Colon and\nRectal Surgery. New York: Springer\n2007:446-449."
    },
    {
        "題別": "單",
        "題號": "33",
        "題目": "在一名患有右側大腸癌的45歲女性患者中，以下何者最能 支持遺傳性非息肉大腸直腸癌的診斷?",
        "選項": [
            "A. 有曾經因子宮頸癌切除子宮病史的妹妹",
            "B. 有曾經因子宮內膜癌切除子宮的個人病史",
            "C. 有肢體黑色素細胞瘤病史的父親",
            "D. 有位在64歲時被診斷出大腸癌的祖父",
            "E. 有表兄弟因家族性腺瘤性息病接受結腸切除術治療"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 693, 1370"
    },
    {
        "題別": "單",
        "題號": "34",
        "題目": "診斷無症狀復發性結直腸癌最常透過連續的：",
        "選項": [
            "A. 血清癌胚胎抗原(CEA)檢測",
            "B. 身體診察",
            "C. 胸部X光",
            "D. 大腸鏡檢查",
            "E. 核磁共振檢查"
        ],
        "答案": "A",
        "出處": "Sabiston 20th e, p. 698"
    },
    {
        "題別": "單",
        "題號": "35",
        "題目": "一名65歲的男性因侵入肌肉固有層, 中度分化的乙狀結腸腺 癌接受乙狀結腸切除術，區域淋巴結共15枚無癌轉移。 並 在結腸旁脂肪發現5毫米的光滑結節，其在顯微鏡下顯示有 微小腺癌。 適當TNM分期是：",
        "選項": [
            "A. T2N0M1",
            "B. T3N1M0",
            "C. T2N0M0",
            "D. T2N1M0",
            "E. T3N1M1"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 1374"
    },
    {
        "題別": "單",
        "題號": "36",
        "題目": "影響無柄管狀腺瘤(Sessile polyp)伴有侵襲性腺癌的淋巴結轉 移的主要危險因素是：",
        "選項": [
            "A. 凹陷型 (depressed morphology)",
            "B. 腸壁侵襲深度",
            "C. 廣泛的腫瘤芽孢形成(extensive budding)",
            "D. 腫瘤大小",
            "E. 絨毛成分"
        ],
        "答案": "B",
        "出處": "Aarons CB, Shanmugan S, Bleier JI.\nManagement of malignant colon polyps:\ncurrent status and controversies. World\nJ Gastroenterol. 2014 Nov\n21;20(43):16178-83. doi:\n10.3748/wjg.v20.i43.16178. PMID:\n25473171; PMCID: PMC4239505."
    },
    {
        "題別": "單",
        "題號": "37",
        "題目": "無法以內鏡切除腸息肉的癌症發病率是多少？",
        "選項": [
            "A. 5%",
            "B. 10%",
            "C. 20%",
            "D. 30%",
            "E. 40%"
        ],
        "答案": "C",
        "出處": "Pokala N, Delaney CP, Kiran RP, Brady K Senagore\nAJ. Outcome of laparoscopic colectomy for polyps not\nsuitable for endoscopic resection. Surg Endosc\n2006;Dec 16 [Epub]\nRoss HM, Li C, Rosenthal J, Kessler J, Fogt F.\nLaparoscopic colon resection for polyps: a good novice\ncase? Dis Colon Rectum 2006;49(6):879-82.\nAlder AC, Hamilton EC, Anthony T, Sarosi GA Jr.\nCancer risk in endoscopically unresectable colon polyps.\nAm J Surg 2006:192(5):644-8.\nMcDonald JM, Moonka R and Bell RH Jr. Pathologic\nrisk factors of occult malignancy in endoscopically\nunresectable colonic adenomas. Am J Surg\n1999;177(5):384-7."
    },
    {
        "題別": "單",
        "題號": "38",
        "題目": "遺傳性非瘜肉病性結直腸癌（HNPCC）癌症中最常見的結 腸外惡性腫瘤是：",
        "選項": [
            "A. 胃癌",
            "B. 卵巢癌",
            "C. 甲狀腺癌",
            "D. 子宮內膜癌",
            "E. 膀胱癌"
        ],
        "答案": "D",
        "出處": "Zhao, S, Chen, L, Zang, Y, et al.\nEndometrial cancer in Lynch\nsyndrome. Int. J. Cancer. 2022; 150(\n1): 7- 17. doi:10.1002/ijc.33763"
    },
    {
        "題別": "單",
        "題號": "39",
        "題目": "在有蒂的息肉中，假性侵犯是指存在有：",
        "選項": [
            "A. 原位癌",
            "B. 固有層中的發育不良的腺體",
            "C. 粘膜下層的發育不良腺體",
            "D. 固有肌層的發育不良腺體",
            "E. 惡性腫瘤的細胞學特徵"
        ],
        "答案": "C",
        "出處": "Burnstein MJ, Hicks TC. Polyps. In: Wolff\nBG, Fleshman JW, Beck DE et al, eds. The\nASCRS Textbook of Colon and Rectal\nSurgery. New York: Springer 2007:362-372\nMuto T Bussey HJR, Morson BC. Pseudo-\ncarcinomatous invasion in adenomatous\npolyps of the colon and rectum. J Clin\nPathol 1973;26:25-31"
    },
    {
        "題別": "單",
        "題號": "40",
        "題目": "對於沒有結直腸腫瘤家族史的45歲女性，最合適的篩檢建 議是：",
        "選項": [
            "A. 每年從50歲開始的軟乙狀結腸鏡檢查",
            "B. 從40歲開始每三年進行一次糞便潛血試驗",
            "C. 空氣對比鋇劑灌腸，從50歲開始每2年一次",
            "D. 結腸鏡每10年一次，從50歲開始",
            "E. 從45歲開始，每5年進行一次結腸鏡檢查"
        ],
        "答案": "D",
        "出處": "Shaukat et al. ACG Clinical Guidelines:\nColorectal Cancer Screening 2021. The\nAmerican Journal of Gastroenterology\n116(3):p 458-479, March 2021. | DOI:\n10.14309/ajg.0000000000001122"
    },
    {
        "題別": "單",
        "題號": "41",
        "題目": "對於40歲男性，有個在61歲時被診斷為結腸癌的姨媽的結 腸癌家族史，最合適的篩查建議是結腸鏡檢查：",
        "選項": [
            "A. 從40歲開始，每10年一次",
            "B. 從50歲開始每10年一次",
            "C. 從40歲開始，每5年一次",
            "D. 從5歲開始，每5年一次",
            "E. 從45歲開始，每5年一次"
        ],
        "答案": "B",
        "出處": "Shaukat et al. ACG Clinical Guidelines:\nColorectal Cancer Screening 2021. The\nAmerican Journal of Gastroenterology\n116(3):p 458-479, March 2021. | DOI:\n10.14309/ajg.0000000000001122"
    },
    {
        "題別": "單",
        "題號": "42",
        "題目": "與術後化放療相比，術前化放療治療直腸癌的特點是：",
        "選項": [
            "A. 相等程度的治療毒性",
            "B. 增進病灶的原位控制",
            "C. 提高總體生存率",
            "D. 腹腔鏡轉換率增加",
            "E. 術後併發症發生率增加"
        ],
        "答案": "B",
        "出處": "Sauer R, Becker H, Hohenberger W, et\nal, and the German Rectal Cancer Study\nGroup. Preoperative versus\npostoperative chemoradiotherapy for\nrectal cancer. N Engl J Med.\n2004,351(17):1731-1740."
    },
    {
        "題別": "單",
        "題號": "43",
        "題目": "在服用FOLFOX化療後，患有III期結腸癌的患者會出現周圍 神經病變。最可能的致病藥物是：",
        "選項": [
            "A. 5-Fluorouracil",
            "B. Oxaliplatin",
            "C. Irinotecan",
            "D. Leucovorin",
            "E. Mitomycin C"
        ],
        "答案": "B",
        "出處": "Andre T, Boni C, Mounedji-Boudiaf L, e al, and\nthe Multicenter International Study of\nOxaliplatin/5-Fluoruracil/Leucovorin in the\nAdjuvant Treatment of Colon Cancer (NİOSAIC)\nInvestigators. Oxaliplatin. fluorouracil, and\nleucovorin as adjuvant treatment for colon cancer.\nN Engl J Med. 2004;35(23);2343-2351\nGoldberg RM, Sargent DJ, Morton RF et al. A\nrandomized controlled trial of fluorouracil plus\nleucovorin, irinotecan, and oxaliplatin\ncombinations in patients with previously\nuntreated metastatic colorectal cancer. J Clin\nOncol. 2004;22(1):22-30."
    },
    {
        "題別": "單",
        "題號": "44",
        "題目": "對於不可切除的轉移性結直腸癌，使用化學治療的的存活 中位數是：",
        "選項": [
            "A. 8個月",
            "B. 12個月",
            "C. 20個月",
            "D. 36 個月",
            "E. 48個月"
        ],
        "答案": "C",
        "出處": "Goldberg RM, Sargent DJ, Morton RF et al. A\nrandomized controlled trial of fluorouracil plus\nleucovorin, irinotecan, and oxaliplatin\ncombinations in patients with previously\nuntreated metastatic colorectal cancer. J Clin\nOncol 2004:22(1): 23-30.Epub 2003 Dec 9.\nTournigand C, Andre T, Achille E et al. FOLFIRI\nfollowed by FOLFOX6 or the reverse sequence in\ncancer: a randomized GERGOR study. J Clin\nOncol 2004,22(2):229-37. Epub 2003 Dec 2.\nHurwitz H, Fehrenbacher L, Novotny W et al.\nBevacizumab plus irinotecan, fluorouracil and\nleucovorin for metastatic colorectal cancer. N\nEngl J Med 2004;350(23):2335-42."
    },
    {
        "題別": "單",
        "題號": "45",
        "題目": "一名72歲的男性因闌尾炎進行腹腔鏡闌尾切除。病理標本 評估顯示闌尾尖端含直徑1厘米的類癌，基部有急性炎症的 變化。以下那一項為最適當的下一步治療？",
        "選項": [
            "A. Right hemicolectomy 右半結腸切除術",
            "B. Laparoscopic lymphadenectomy 腹腔鏡淋巴結切除術",
            "C. Administration of octreotide 奧曲肽的給藥",
            "D. Systemic chemotherapy全身化療",
            "E. No further treatment 無需進一步的治療"
        ],
        "答案": "E",
        "出處": "Sabiston 20th e, p. 1308"
    },
    {
        "題別": "單",
        "題號": "46",
        "題目": "一名74歲的男性切除結腸類癌腫瘤一年後，被診斷患有另 一種惡性腫瘤。以下那個是最有可能的部位？",
        "選項": [
            "A. 結腸",
            "B. 前列腺",
            "C. 肺",
            "D. 乳房",
            "E. 腦"
        ],
        "答案": "C",
        "出處": "Tichansky DS, Cagir B, Borrazzo E, et al\nRisk of second cancers in patients with\ncolorectal carcinoids. Dis Colon Rectum.\n2002, 45(1):91-97。\nModlin IM, Latich I, Kidd M, et al.\nTherapeutic options for gastrointestinal\ncarcinoids. Clin Gastroenterol hepatol 2006,\n4(5):526-47"
    },
    {
        "題別": "單",
        "題號": "47",
        "題目": "關於大腸癌標靶藥物治療之敘述，何者是錯的？",
        "選項": [
            "A. 轉移性大腸癌合併使用化學治療及標靶治療 可明顯提升 存活率。",
            "B. 大腸手術後過早使用Avastin可能增加出血機會 及影響傷 口癒合。",
            "C. Avastin使用期間可能增加動脈血栓栓塞之風險。",
            "D. Erbitux使用於EGFR(+)及KRAS mutations(+) 之病患。",
            "E. Erbitux最主要副作用為皮膚反應。"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 314, 721, 1377"
    },
    {
        "題別": "單",
        "題號": "48",
        "題目": "下列何者遺傳性疾病／癌症與其突變基因配對有誤？",
        "選項": [
            "A. Breast/ovarian syndrome → BRCA1、BRCA2",
            "B. Hereditary diffuse gastric cancer → CDH1",
            "C. Familial adenomatous polyposis → MET",
            "D. Retinoblastoma → RB",
            "E. Peutz-Jeghers syndrome → STK11"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 691"
    },
    {
        "題別": "單",
        "題號": "49",
        "題目": "下列何者標靶藥物與其作用標的配對有誤？",
        "選項": [
            "A. Cetuximab → EGFR",
            "B. Bevacizumab → VEGF",
            "C. Denosumab → CTLA-4",
            "D. Pertuzumab → HER2",
            "E. Pembrolizmab → PD-1"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 719"
    },
    {
        "題別": "單",
        "題號": "50",
        "題目": "下列關於BRCA1/2基因的敘述，何者錯誤？",
        "選項": [
            "A. BRCA1/2基因突變引起之遺傳性乳癌，佔所有乳癌比例 約5-10％。",
            "B. BRCA1/2基因突變引起之相關癌症，不包含prostate cancer。",
            "C. BRCA1位於chromosome 17。",
            "D. BRCA1和BRCA2都是tumor suppresor genes。",
            "E. BRCA1/2基因突變的主要致癌機轉是去活化DNA damage repair的功能。"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 693"
    },
    {
        "題別": "單",
        "題號": "51",
        "題目": "下列何者標靶藥物與其治療適應症之配對有誤？",
        "選項": [
            "A. Rituximab - Non-Hodgkin lymphoma",
            "B. Certikuzymab pego - Crohn's disease",
            "C. Ipilimumab - Metastatic melanoma",
            "D. Trastuzumab emtansine - Acute myeloid leukemia",
            "E. Panitumumab - Colorectal cancer"
        ],
        "答案": "D",
        "出處": "Sabiston 20th e, p. 719"
    },
    {
        "題別": "單",
        "題號": "52",
        "題目": "下列關於Cancer Immunoediting的過程，那一階段以具有 降低免疫原性 (immunogenicity) 且能逃避免疫識别 (immune recognition) 為特徵？",
        "選項": [
            "A. Elimination phase",
            "B. Equilibrium phase",
            "C. Escape phase",
            "D. Activation phase",
            "E. Recognition phase"
        ],
        "答案": "C",
        "出處": "Sabiston 20th e, p. 688"
    },
    {
        "題別": "單",
        "題號": "53",
        "題目": "下列關於乳癌標靶／免疫藥物的使用，何者有誤？",
        "選項": [
            "A. 轉移性HER2強陽性乳癌，紫杉醇類藥物加上賀癌平 (Trastuzumab)以及賀疾妥 (Pertuzumab)為第一線治療。",
            "B. 轉移性HER2陽性乳癌的第二線治療，仍為Ado- trastuzumab emtansine (T-DM1)。",
            "C. CDK 4/6 inhibitors",
            "D. 轉移性三陰性乳癌，在測得PD-L1 CPS ≥ 10的情況下， Pembrolizumab搭配化療為第一線治療。",
            "E. Fam-trastuzumab deruxtecan相較於化療，已被證實治 療轉移性HER2弱陽性乳癌有較好的存活率。"
        ],
        "答案": "B",
        "出處": "NCCN Guidelines Version 4.2023,\nBreast Cancer"
    },
    {
        "題別": "單",
        "題號": "54",
        "題目": "以下哪個選項不是關於誘導細胞凋亡途徑 (Apoptosis) 的正 確描述？",
        "選項": [
            "A. 通過受體依賴途徑引發細胞外刺激 (extracellular stress)。",
            "B. 通過受體非依賴途徑引發細胞外刺激 (extracellular stress)。",
            "C. 從粒線體釋放cytochrome C。",
            "D. 按順序激活多種細胞凋亡酶 (caspases)。",
            "E. 抑制cytochrome C從粒線體釋放。"
        ],
        "答案": "E",
        "出處": "Sabiston 20th e, p. 684"
    },
    {
        "題別": "單",
        "題號": "55",
        "題目": "下列關於大腸癌藥物治療之敘述，何者正確？",
        "選項": [
            "A. pT2N0、pMMR/MMS形態的大腸癌患者，術後規律追 蹤即可。",
            "B. pT3N0、pMMR/MMS形態的大腸癌患者，術後必須接 受靜脈化學藥物治療，不可單使用口服化療。",
            "C. 影像及臨床判斷為T4b、腫瘤型態為dMMR/MSI-H之大 腸癌患者，可考慮接受術前藥物治療，免疫治療的選項包 含Atezolizumab。",
            "D. pT1N0、dMMR/MSI-H形態的大腸癌患者，術後必須接 受化學藥物治療。",
            "E. 第四期之dMMR/MSI-H型態大腸癌患者，僅能接受藥物 治療，手術治療對於治療成績沒有幫助。"
        ],
        "答案": "A",
        "出處": "NCCN Guidelines Version 2.2023,\nColon Cancer, COL-4, 13, 15"
    },
    {
        "題別": "單",
        "題號": "56",
        "題目": "下列關於台灣女性乳癌的疾病特性，何者有誤？",
        "選項": [
            "A. 年齡別發生率的高峰介於60-75歲之間。",
            "B. 相較於歐美國家而言，台灣女性乳癌的發病年齡較為年 輕。",
            "C. 台灣女性乳癌的死亡率隨著年紀逐年上升。",
            "D. 年齡別發生率的高峰介於45-65歲之間。",
            "E. 老年乳癌患者接受標準治療的比例較低。"
        ],
        "答案": "A",
        "出處": "國健署109年度癌症登記檔案"
    },
    {
        "題別": "單",
        "題號": "57",
        "題目": "下列關於大腸直腸癌治療後追蹤的建議，何者正確？",
        "選項": [
            "A. CEA (carcinoembryonic antigen) 的指數上升，與是否 有復發可能性無關。",
            "B. 第一期大腸癌手術後一年建議追蹤大腸鏡。",
            "C. 手術後五年內建議追蹤的檢查項目，包含CA-153以及正 子掃描。",
            "D. 大腸癌遠端復發後，不需再追蹤CEA (carcinoembryonic antigen)。",
            "E. 大腸癌術後追蹤大腸鏡時，若發現有advanced adenoma，切除即可，不需追蹤。"
        ],
        "答案": "B",
        "出處": "NCCN Guidelines Version 2.2023,\nColon Cancer"
    },
    {
        "題別": "單",
        "題號": "58",
        "題目": "下列關於一級致癌物以及主要引發的癌症類型，何者錯 誤？",
        "選項": [
            "A. 石綿 - 肺癌",
            "B. 苯 - 胃癌",
            "C. 鎳 - 鼻癌",
            "D. 焦煤油 - 皮膚癌",
            "E. 菸 - 食道癌"
        ],
        "答案": "B",
        "出處": "Sabiston 20th e, p. 695"
    },
    {
        "題別": "單",
        "題號": "59",
        "題目": "下列關於BRCA1/2基因變異引發相關癌症治療之敘述，何 者正確？",
        "選項": [
            "A. Olaparib、Talazoparib、Verliparib均有助於改善帶有 BRCA1/2 germline mutated metastatic breasrt cancer的 整體存活率 (overall survival) 。",
            "B. Olaparib對於BRCA1/2 germline mutated early breasrt cancer患者無法達到改善整體存活率的效果。",
            "C. Rucaparib可用於治療對於帶有BRCA1/2基因變異且對 去勢療法無效之晚期攝護腺癌。",
            "D. 腫瘤小於0.5公分之BRCA1/2 germline mutated early breasrt cancer患者建議也要使用Olaparib，才能顯著改善 預後。",
            "E. BRCA1/2 germline mutated early prostate cancer患者 也建議使用Rucaparib或Olaparib來改善預後。"
        ],
        "答案": "C",
        "出處": "NCCN Guidelines Version 4.2023,\nBreast cancer; NCCN Guidelines\nVersion 1.2023, Prostate cancer"
    }
]